Payment overview · 2025
General Payments
$1,685.22
62 reported records · 18 companies
Healthcare provider profile · identity verified
Afrouz S. Gerayli, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CAMARILLO, CA · NPI 1801044839
Verified facts
What the public records show
CMS Open Payments records show Afrouz S. Gerayli, MD received $1,685.22 in general payments during 2025 across 62 reported records.
ABBVIE INC. accounted for 19.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Jardiance, Mounjaro, Nexletol, Ozempic, Prolia, Rybelsus, Shingrix, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 147 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $334.66 | 19.9% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $270.55 | 16.1% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $262.94 | 15.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $238.38 | 14.2% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $118.66 | 7.0% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $92.40 | 5.5% | 4 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $50.98 | 3.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.33 | 2.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.14 | 2.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $39.48 | 2.3% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $37.11 | 2.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $30.47 | 1.8% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $29.35 | 1.7% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.68 | 1.4% | 1 | 2025 |
| IBSA Pharma Inc. | Unresolved — no canonical attribution shown | $20.49 | 1.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $15.05 | 0.9% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $14.80 | 0.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $13.75 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,685.22 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $247.69 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $192.52 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $185.34 | 11 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $165.32 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $158.44 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $140.74 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $135.58 | 1 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $122.20 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $76.45 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $73.06 | 9 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $70.70 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $70.70 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $70.70 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $65.63 | 4 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $50.98 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $48.33 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $39.48 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $37.11 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.77 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $30.47 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $30.47 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $29.35 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $26.21 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.82 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $24.62 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.68 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $21.70 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.55 | 1 | 2025 |
Source payment records
|
|||||
| Flector Normalized: flector |
Drug | IBSA Pharma Inc. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| Licart Normalized: licart |
Drug | IBSA Pharma Inc. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| Tirosint Normalized: tirosint |
Drug | IBSA Pharma Inc. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.17 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $14.80 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $13.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 178 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 147 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 222 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 249 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 44 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 45 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 138 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
138 | 41 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
44 | 26 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
178 | 43 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 39 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
147 | 39 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
222 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
249 | 46 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
31 | 31 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 892 | 246 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 871 | 231 |
| Levothyroxine Sodium | Levothyroxine Sodium | 763 | 190 |
| Atorvastatin Calcium | Atorvastatin Calcium | 507 | 143 |
| Metformin Hcl | Metformin Hcl | 476 | 125 |
| Valsartan | Valsartan | 472 | 134 |
| Metoprolol Succinate | Metoprolol Succinate | 403 | 114 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 371 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 367 | 104 |
| Omeprazole | Omeprazole | 339 | 88 |
| Losartan Potassium | Losartan Potassium | 310 | 90 |
| Simvastatin | Simvastatin | 284 | 69 |
| Tamsulosin Hcl | Tamsulosin Hcl | 263 | 71 |
| Gabapentin | Gabapentin | 249 | 83 |
| Ozempic | Semaglutide | 249 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 230 | 72 |
| Mounjaro | Tirzepatide | 222 | 31 |
| Trazodone Hcl | Trazodone Hcl | 216 | 72 |
| Meloxicam | Meloxicam | 195 | 75 |
| Escitalopram Oxalate | Escitalopram Oxalate | 186 | 51 |
| Hydralazine Hcl | Hydralazine Hcl | 186 | 70 |
| Farxiga | Dapagliflozin Propanediol | 178 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 175 | 83 |
| Citalopram Hbr | Citalopram Hydrobromide | 170 | 45 |
| Nebivolol Hcl | Nebivolol Hcl | 163 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 156 | 90 |
| Januvia | Sitagliptin Phosphate | 156 | 41 |
| Lisinopril | Lisinopril | 156 | 46 |
| Eliquis | Apixaban | 155 | 33 |
| Furosemide | Furosemide | 152 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 147 | 46 |
| Jardiance | Empagliflozin | 147 | 39 |
| Ezetimibe | Ezetimibe | 140 | 41 |
| Synthroid | Levothyroxine Sodium | 138 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 130 | 32 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 29 |
| Alprazolam | Alprazolam | 120 | 46 |
| Allopurinol | Allopurinol | 112 | 31 |
| Tramadol Hcl | Tramadol Hcl | 109 | 27 |
| Potassium Chloride | Potassium Chloride | 107 | 30 |
| Celecoxib | Celecoxib | 106 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 102 | 77 |
| Xarelto | Rivaroxaban | 101 | 20 |
| Azithromycin | Azithromycin | 99 | 87 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 19 |
| Metformin Hcl Er | Metformin Hcl | 93 | 29 |
| Repatha Sureclick | Evolocumab | 91 | 20 |
| Finasteride | Finasteride | 89 | 25 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 46 |
| Sertraline Hcl | Sertraline Hcl | 82 | 24 |
| Donepezil Hcl | Donepezil Hcl | 79 | 14 |
| Famotidine | Famotidine | 78 | 20 |
| Montelukast Sodium | Montelukast Sodium | 77 | 26 |
| Methylprednisolone | Methylprednisolone | 75 | 69 |
| Chlorthalidone | Chlorthalidone | 74 | 25 |
| Doxazosin Mesylate | Doxazosin Mesylate | 74 | 14 |
| Propranolol Hcl | Propranolol Hcl | 70 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 69 | 35 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 69 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | 11 |
| Warfarin Sodium | Warfarin Sodium | 64 | 12 |
| Estradiol | Estradiol | 63 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 34 |
| Atenolol | Atenolol | 60 | 15 |
| Myrbetriq | Mirabegron | 60 | 11 |
| Carvedilol | Carvedilol | 58 | 16 |
| Cefdinir | Cefdinir | 57 | 46 |
| Digoxin | Digoxin | 55 | 13 |
| Clonazepam | Clonazepam | 53 | 11 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 53 | 16 |
| Memantine Hcl | Memantine Hcl | 52 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 52 | 15 |
| Icosapent Ethyl | Icosapent Ethyl | 50 | 14 |
| Lorazepam | Lorazepam | 50 | 19 |
| Cephalexin | Cephalexin | 49 | 34 |
| Mirtazapine | Mirtazapine | 49 | 15 |
| Alendronate Sodium | Alendronate Sodium | 47 | 14 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 13 |
| Rybelsus | Semaglutide | 45 | suppressed |
| Prolia | Denosumab | 44 | 26 |
| Benazepril Hcl | Benazepril Hcl | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 13 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 38 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 12 |
| Spironolactone | Spironolactone | 37 | 13 |
| Valacyclovir | Valacyclovir Hcl | 37 | 20 |
| Bethanechol Chloride | Bethanechol Chloride | 36 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 12 |
| Risedronate Sodium | Risedronate Sodium | 36 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 34 | 13 |
| Fluconazole | Fluconazole | 33 | 17 |
| Pregabalin | Pregabalin | 33 | suppressed |
| Vascepa | Icosapent Ethyl | 33 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 31 | 31 |
| Azelastine Hcl | Azelastine Hcl | 30 | 14 |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Telmisartan | Telmisartan | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Testosterone | Testosterone | 29 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 29 | 12 |
| Prednisone | Prednisone | 28 | 23 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Kerendia | Finerenone | 27 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | 12 |
| Irbesartan | Irbesartan | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 17 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Livalo | Pitavastatin Calcium | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Klor-Con 10 | Potassium Chloride | 16 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Nexletol | Bempedoic Acid | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Dayvigo | Lemborexant | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | 14 |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Progesterone | Progesterone, Micronized | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Bumetanide | Bumetanide | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Tegretol | Carbamazepine | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,685.22 · 62 records | ABBVIE INC. | ABRYSVO, ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, EVENITY, FARAPULSE, FARXIGA, FREESTYLE LIBRE 3, Flector, JARDIANCE, JOURNAVX, KISUNLA, LEQVIO, LINZESS, Licart, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, SHINGRIX, SYNTHROID, Tirosint, Tymlos, UBRELVY, WATCHMAN FLX, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error